NextPharma
NextPharma is a Europe-based pharmaceutical CDMO operating 10 manufacturing centres of excellence across the UK, France, Germany, Finland, and Norway, offering development, clinical trials supply, commercial manufacturing, and analytical services across a wide range of dosage forms to pharma, biotech, and nutraceutical companies.
- Company typePrivate
- Founded2021
- HeadquartersWokingham, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What NextPharma does
NextPharma is a European pharmaceutical contract development and manufacturing organization (CDMO) headquartered in London and operating 10 manufacturing centres of excellence across the United Kingdom, France, Germany, Finland, and Norway. The company offers five core service lines — Pharmaceutical Development, Clinical Trials Services, Commercial Manufacturing & Packaging, Health & Nutrition, and Analytical & Microbiological Services — delivering across a broad range of dosage forms including softgel and liquid-filled hard capsules (Licaps), lipid-based formulations, tablets, liquids, suppositories, cephalosporins, penicillins, hormones, ophthalmics, and chewable tablets. Aggregated disclosed capacity is in the multi-billion unit range (e.g., ~4 billion tablets/year at Göttingen Solids, ~3.9 billion softgel capsules/year at Ploërmel, 3 million litres/year liquids at Limay).
NextPharma firmographics
Firmographics- Name
- NextPharma
- Legal name
- NextPharma Technologies
- Website
- https://nextpharma.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- NextPharma is a Europe-based pharmaceutical CDMO operating 10 manufacturing centres of excellence across the UK, France, Germany, Finland, and Norway, offering development, clinical trials supply, commercial manufacturing, and analytical services across a wide range of dosage forms to pharma, biotech, and nutraceutical companies.
- Ownership category
- akta.pro rank
NextPharma industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where NextPharma is headquartered
LocationHeadquarters
- HQ city
- Wokingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices11 records
Markets served
NextPharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Revenue generated from providing pharmaceutical development and manufacturing services to pharmaceutical, biotech, and nutraceutical companies under contract manufacturing agreements
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
NextPharma product offering
Product offeringCore offering
NextPharma is a European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) that provides formulation development, clinical trial supply, commercial manufacturing, and packaging of solid, liquid, semi-solid, and specialised dosage forms (including softgels, tablets, suppositories, cephalosporins, penicillins, hormones, and ophthalmics) for pharmaceutical, biotech, and nutraceutical customers. Services are delivered through 10 specialised centres of excellence across the UK, France, Germany, Finland, and Norway under GMP conditions with EMA, US FDA, and ANVISA regulatory approvals.
Product overview
NextPharma is a Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical development and manufacturing services across Europe. The company operates as a platform of specialized sites rather than a single product, providing five core services: Pharmaceutical Development (formulation and technical transfer), Clinical Trials Services (supply chain for trials), Commercial Manufacturing & Packaging (solid, liquid, and semi-solid dosage forms), Health and Nutrition (food supplements and softgels), and Analytical and Microbiological Services (quality control and stability testing). These services are delivered through a network of nine manufacturing centres of excellence across Europe, including specialized facilities for lipid-based formulations and softgels in Ploërmel (France), liquids and suppositories in Limay (France), cephalosporins and solids in Göttingen (Germany), and additional sites for penicillins, modified release, hormones, ophthalmics, and chewable tablets.
Differentiator
Problem solved
Functional benefit
Brands
- Licaps: Licaps technology for pharmaceutical products - liquid-filled hard capsules for OTC and Rx products
Products and services
- Pharmaceutical Development Contract development services supporting drug development projects from early stages through manufacturing, including formulation development and technical transfer for pharmaceutical and biotech customers.
- Clinical Trials Services Flexible clinical trial supply services including manufacturing, packaging, and distribution for clinical trial programs, provided from the Göttingen Solids & CTS centre of excellence.
- Commercial Manufacturing & Packaging Contract manufacturing and packaging services across multiple dosage forms including tablets, capsules, liquids, suppositories, and specialty forms, supporting commercial supply requirements for pharma and biotech customers.
- Health & Nutrition European contract development and manufacturing partner for food supplements, providing nutritional solutions and softgel manufacturing for nutraceutical companies.
- Analytical & Microbiological Services Analytical and microbiological testing services to support product development, quality control, and stability studies, offered as a CDMO service.
Companies that use NextPharma
Customer profileSegments2 records
Ideal customer profiles2 records
NextPharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
NextPharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major and core.
- CencoramajorNextPharma sold its logistics arm to Cencora as part of a strategic repositioning to become Europe's leading pure-play CDMO. The transaction was announced on October 13, 2025, and completed as part of NextPharma's strategy to focus on core pharmaceutical development and manufacturing services.
- TakedacoreNextPharma partnered with Takeda to acquire the pharmaceutical manufacturing site in Asker, Norway, announced in September 2022 and completed in April 2023. This acquisition expanded NextPharma's chewable tablets capabilities and established a centre of excellence in Norway.
- LonzacoreNextPharma completed acquisition of two Lonza sites specialized in lipid oral dosage forms in April 2021, including the Ploërmel site in France, significantly expanding softgel and lipid-based formulation capabilities.
Scale indicators10 records
Recent moves7 records
Expansion highlights4 records
NextPharma competitors and assessment
Company assessmentDirect peers
- Catalent: Global pure-play CDMO with deep softgel, oral solid and sterile fill-finish capabilities. Direct competitor in lipid-based formulations and oral dose; multiple NextPharma senior leaders (CCO, COO) joined from Catalent.
- Aenova Group: Germany-headquartered CDMO focused on solid and semi-solid dosage forms, including softgels. Closest geographic and capability peer to NextPharma, with overlapping European customer base in pharma and nutraceuticals.
- Recipharm: Swedish CDMO offering development, manufacturing and clinical supply services across multiple dosage forms. Comparable European platform with similar mix of acquired legacy pharma sites and a focus on oral solids, semi-solids and injectables.
- Delpharm: France-based CDMO with a broad European network of manufacturing sites serving pharma clients on solid, liquid and sterile forms. Direct competitor for French and pan-European contract manufacturing opportunities.
- Fareva: French private CDMO with extensive European manufacturing footprint across pharmaceutical, cosmetic and specialty dosage forms. Comparable business model as a multi-site European contract manufacturer serving big pharma.
- Corden Pharma: Full-service CDMO with strong capabilities in oral solid dose, sterile injectables, peptides and highly potent APIs. Direct competitor; NextPharma's COO previously served as Managing Director of Corden Pharma GmbH.
- Siegfried Holding: Swiss-listed CDMO with European and US sites covering small-molecule API and finished dose manufacturing. Comparable platform of acquired legacy pharma sites, similar customer base in branded and generic pharmaceuticals.
- Hovione: Portuguese CDMO specialising in API development, particle engineering and oral/inhalation dosage forms. Comparable in scale and customer mix, with overlapping expertise in complex small-molecule formulations.
Broad incumbents
- Thermo Fisher Scientific (Patheon): Global CDMO division of Thermo Fisher offering a full spectrum of development, clinical and commercial manufacturing services. Not a pure-play CDMO; overlaps with NextPharma in oral solid dose, softgels and clinical supply but operates at materially larger scale.
- Lonza: Global CDMO leader with capabilities spanning small molecules, biologics and cell & gene therapies. Sold its lipid/softgel Ploërmel site to NextPharma in 2021, making Lonza a former owner of a key NextPharma asset as well as a broader-sector competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
NextPharma social profiles
Digital presenceNextPharma compliance and trust
Trust signalCompliance14 records
NextPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
NextPharma leadership team
Management profileNumber of profiles
Profiles9 records
NextPharma subsidiaries and ownership
Company hierarchySubsidiaries11 records
NextPharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NextPharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NextPharma
What does NextPharma do?
NextPharma is a European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) that provides formulation development, clinical trial supply, commercial manufacturing, and packaging of solid, liquid, semi-solid, and specialised dosage forms (including softgels, tablets, suppositories, cephalosporins, penicillins, hormones, and ophthalmics) for pharmaceutical, biotech, and nutraceutical customers. Services are delivered through 10 specialised centres of excellence across the UK, France, Germany, Finland, and Norway under GMP conditions with EMA, US FDA, and ANVISA regulatory approvals.
Is NextPharma a public or private company?
NextPharma is a private company. It is classified as private equity controlled and is currently operating.
When was NextPharma founded?
NextPharma was founded in 2021. It employs 1,001 to 5,000 people.
Where is NextPharma based?
NextPharma is headquartered in Wokingham, United Kingdom, in the Europe region.
How does NextPharma make money?
One revenue line is on record: contract Manufacturing Services.
Who are NextPharma's main competitors?
Direct peers on record are Catalent, Aenova Group, Recipharm, Delpharm, Fareva, Corden Pharma, Siegfried Holding and Hovione. Broad incumbents are Thermo Fisher Scientific (Patheon) and Lonza.
Does NextPharma have an API?
No public API is recorded for NextPharma.
What industry is NextPharma in?
NextPharma's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.